ClinDatrix, Inc was contracted by Valeant Pharmaceuticals International, Inc. to provide full service clinincal research contracting for their phase 3 study of renu®. Valeant Pharmaceuticals is a wholly owned subsidiary, of Bausch + Lomb, a leading global eye health company. Renu® is a New & Improved Formula Builds on Trusted 30-Year Heritage of Meeting Consumers’ Lens …
ClinDatrix Contract Research Organization Launches Oracle Health Sciences InForm 6.1 and Oracle Argus 8.0 to Speed Clinical Trials and Support Global Safety Collection and Risk Management Efforts
ClinDatrix, a leading full service contract research organization (CRO) located in Irvine, California, launches Oracle Health Sciences InForm 6.1 and Oracle Argus 8.0, to improve clinical development processes, streamline data capture, speed up trial timelines and enhance pharmacovigilance services. ClinDatrix is a full service CRO offering pre-clinical and clinical Phase I-IV project management services for …
ClinDatrix Joins Six Other CROs to Provide Global Services
Collaboration Will Ensure Local Monitoring and Centralized Clinical Research Technology for Sponsors of Multinational Clinical Trials IRVINE, CA, May 15, 2014 – ClinDatrix, Inc. has signed collaboration agreements with six contract research organizations (CROs) from around the world to form a consortium that offers services for multinational clinical trials. On joint projects, consortium members will …
ClinDatrix Joins Six Other CROs to Provide Global ServicesRead More
Steve Balyakin, MD, PHD, FFPM, CMC Named Senior Medical Director for ClinDatrix, INC.
IRVINE, CA, July 23, 2013 – Steve Balyakin, MD, PhD, FFPM, CMC, recently was named Senior Medical Director of ClinDatrix, Inc. He will lead the patient safety and medical monitoring activities for the Irvine-based contract research organization (CRO). Prior to accepting the full-time position, Dr. Balyakin provided medical monitoring as aconsultant to ClinDatrix. “Steve has …
Steve Balyakin, MD, PHD, FFPM, CMC Named Senior Medical Director for ClinDatrix, INC.Read More
Sineth Desai Joins ClinDatrix, Inc.; CRO Veteran to Lead Clinical Operations
IRVINE, CA, October 16, 2012 – Sineth Desai recently joined ClinDatrix, Inc. to head the Irvine-based contract research organization’s clinical department. In her new role as Director of Clinical Operations, Desai will serve as the key contact to the company’s clinical monitoring clients, oversee the firm’s clinical research associates and guide the expansion of the …
Sineth Desai Joins ClinDatrix, Inc.; CRO Veteran to Lead Clinical OperationsRead More
Two ClinDatrix Executives Earn Their Certified Quality Auditor Certifications
IRVINE, CA, June 19, 2012 – ClinDatrix, Inc. announced today that two members of its executive team – Louise M. Murphy, PhD, MBA, and Ned Whittemore, PhD – have earned their Certified Quality Auditor (CQA) certifications from the American Society for Quality (ASQ). The certification, which requires intensive training and successful completion of a rigorous …
Two ClinDatrix Executives Earn Their Certified Quality Auditor CertificationsRead More
Ground Zero Pharmaceuticals Announces Milestones In Pharmaceutical And Biotechnology Outsourcing Services
IRVINE, Calif., Nov. 8 /PRNewswire/ — The climate for pharmaceutical and biotechnology products has changed with increased emphasis on integrated product development, FDA reorganization, and recognition of the need for early markers of safety. Combination products are a major growth area. Strategic global planning and cost-effective development programs can lead to timely FDA approvals. The …
BioGentech Announces ClinDatrix as CRO for Phase III Trials
IRVINE, Calif., April 29, 2004 (PRIMEZONE) — BioGentech Corp. (OTCBB:BGTH), a pharmaceutical company specializing in over-the-counter anti-allergy medications, announced today that it has entered into an agreement with Irvine based ClinDatrix, Inc. for the implementation, management and analysis of clinical investigations of BioGentech’s flagship product, Prehistin, for their upcoming Phase III trials. The Phase III …
BioGentech Announces ClinDatrix as CRO for Phase III TrialsRead More